BEXIMCO PHARMA.GDR REGS 1 Market Cap ($208.62 Million)
Market Cap & Net Worth: BEXIMCO PHARMA.GDR REGS 1 (R2WA)
BEXIMCO PHARMA.GDR REGS 1 market cap. BEXIMCO PHARMA.GDR REGS 1 (F:R2WA) has a market capitalization of $208.62 Million (€178.44 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #16206 globally and #1546 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BEXIMCO PHARMA.GDR REGS 1's stock price €0.40 by its total outstanding shares 446112089 (446.11 Million). Also see BEXIMCO PHARMA.GDR REGS 1 cash flow conversion for how efficiently the company converts equity into cash flow.
BEXIMCO PHARMA.GDR REGS 1 Market Cap History (2015–2026)
BEXIMCO PHARMA.GDR REGS 1 market cap history from 2015 to 2026. Data shows growth from $93.04 Million to $208.62 Million (10.13% CAGR). Check BEXIMCO PHARMA.GDR REGS 1 stock quote for real-time trading data and today's change.
BEXIMCO PHARMA.GDR REGS 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BEXIMCO PHARMA.GDR REGS 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BEXIMCO PHARMA.GDR REGS 1 (R2WA) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
BEXIMCO PHARMA.GDR REGS 1's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.04x
BEXIMCO PHARMA.GDR REGS 1's market cap is 0.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $522.60 Million | $29.49 Billion | $5.13 Billion | 0.02x | 0.10x |
| 2022 | $259.89 Million | $34.67 Billion | $5.12 Billion | 0.01x | 0.05x |
| 2023 | $208.15 Million | $39.27 Billion | $4.61 Billion | 0.01x | 0.05x |
| 2024 | $215.92 Million | $44.39 Billion | $5.83 Billion | 0.00x | 0.04x |
Competitor Companies of R2WA by Market Capitalization
Companies near BEXIMCO PHARMA.GDR REGS 1 in the global market cap rankings as of November 4, 2026. Also see BEXIMCO PHARMA.GDR REGS 1 assets under control for a full breakdown of the balance sheet.
Key companies related to BEXIMCO PHARMA.GDR REGS 1 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of BEXIMCO PHARMA.GDR REGS 1 (2015–2026)
Market capitalization of BEXIMCO PHARMA.GDR REGS 1 from 2015 to today. Between 2015 and today, BEXIMCO PHARMA.GDR REGS 1's market cap moved from $93.04 Million to $ 208.62 Million, with a yearly change of 10.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €208.62 Million | 0.00% |
| 2025 | €208.62 Million | -3.38% |
| 2024 | €215.92 Million | +3.73% |
| 2023 | €208.15 Million | -19.91% |
| 2022 | €259.89 Million | -50.27% |
| 2021 | €522.60 Million | +22.85% |
| 2020 | €425.38 Million | +124.31% |
| 2019 | €189.64 Million | +12.26% |
| 2018 | €168.93 Million | -22.31% |
| 2017 | €217.43 Million | +7.67% |
| 2016 | €201.94 Million | +117.04% |
| 2015 | €93.04 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of BEXIMCO PHARMA.GDR REGS 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $208.62 Million USD |
| MoneyControl | $208.62 Million USD |
| MarketWatch | $208.62 Million USD |
| marketcap.company | $208.62 Million USD |
| Reuters | $208.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more